The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
Faster thinning of cpRNFL and mGCIPL is associated with visual field progression in glaucoma, with rates of –1.02 and –1.04 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback